Literature DB >> 22964514

Disease mechanisms in MS: phases of disease improvement unrelated to relapses.

Oluf Andersen1.   

Abstract

Natural history of multiple sclerosis includes phases of relapse, remission and insidious progression. New data show that sustained improvements in disease, defined by reductions in EDSS scores, occur independent of relapses almost half as frequently as disease worsening. This finding might facilitate research into the biological processes involved in disease improvement.

Entities:  

Mesh：

Year:  2012        PMID： 22964514     DOI： 10.1038/nrneurol.2012.186

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


  10 in total

1.  Disability as an outcome in MS clinical trials.

Authors:  G C Ebers; L Heigenhauser; M Daumer; C Lederer; J H Noseworthy
Journal:  Neurology       Date:  2008-05-14       Impact factor: 9.910

2.  Variability of central conduction in the course of multiple sclerosis. Serial recordings of evoked potentials in the evaluation of therapy.

Authors:  A W de Weerd
Journal:  Clin Neurol Neurosurg       Date:  1987       Impact factor: 1.876

3.  Natural, innate improvements in multiple sclerosis disability.

Authors:  Helen Tremlett; Feng Zhu; John Petkau; Joel Oger; Yinshan Zhao
Journal:  Mult Scler       Date:  2012-06-26       Impact factor: 6.312

4.  Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results.

Authors: 
Journal:  Neurology       Date:  2001-06-12       Impact factor: 9.910

5.  Day-to-day variability of maximum walking distance in MS patients can mislead to relevant changes in the Expanded Disability Status Scale (EDSS): average walking speed is a more constant parameter.

Authors:  H Albrecht; C Wötzel; L P Erasmus; M Kleinpeter; N König; W Pöllmann
Journal:  Mult Scler       Date:  2001-04       Impact factor: 6.312

6.  Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohorts.

Authors:  C Liu; L D Blumhardt
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-04       Impact factor: 10.154

7.  Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.

Authors:  Alasdair J Coles; Edward Fox; Anton Vladic; Suzanne K Gazda; Vesna Brinar; Krzysztof W Selmaj; Ann Doan-Do Bass; Daniel R Wynn; David H Margolin; Stephen L Lake; Susan Moran; Jeffrey Palmer; M Shelton Smith; D Alastair S Compston
Journal:  Lancet Neurol       Date:  2011-04       Impact factor: 44.182

Review 8.  Influence of temperature changes on multiple sclerosis: critical review of mechanisms and research potential.

Authors:  T C Guthrie; D A Nelson
Journal:  J Neurol Sci       Date:  1995-03       Impact factor: 3.181

9.  Double-masked trial of azathioprine in multiple sclerosis. British and Dutch Multiple Sclerosis Azathioprine Trial Group.

Authors: 
Journal:  Lancet       Date:  1988-07-23       Impact factor: 79.321

10.  Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

Authors:  L D Jacobs; D L Cookfair; R A Rudick; R M Herndon; J R Richert; A M Salazar; J S Fischer; D E Goodkin; C V Granger; J H Simon; J J Alam; D M Bartoszak; D N Bourdette; J Braiman; C M Brownscheidle; M E Coats; S L Cohan; D S Dougherty; R P Kinkel; M K Mass; F E Munschauer; R L Priore; P M Pullicino; B J Scherokman; R H Whitham
Journal:  Ann Neurol       Date:  1996-03       Impact factor: 10.422
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.